, and an increased risk of high between day variation (OR= 6.6). Conclusions -Subject-reported symptoms are related to impaired lung function and to increased variability of peak flow. (Thorax 1995;50:121-126) 
A considerable proportion of the adult population in western society is affected by chronic obstructive lung disease. Depending on the definition, 5-10% of younger adults (20-45 years of age) suffer from mild to severe asthma. In older age groups symptoms such as chronic expectoration are common. In the elderly prevalence rates are high' 2 and increase with age. In several population studies of subjects above 60 years 30-60% reported one or more chronic respiratory symptom such as chronic cough or phlegm, dyspnoea, persistent wheeze, or chest tightness. Spirometric tests often reveal severe impairment of lung function and the clinical prognosis, in terms of mortality risk, is unfavourable for these subjects. 34 Symptoms are generally the primary reason for consultation with a doctor. The general practitioner will restrict diagnostic activities to a medical history and examination. In most cases spirometric tests will not be performed. Chronic respiratory symptoms are associated with diminished lung function and increased airway lability.5 Once lung function impairment has been quantified by measurement of the FEV, or PEF variability, any further changes -such as decline in lung function or improvement as a result of interventions -can be monitored. Although simple lung function equipment is becoming increasingly available, it remains uncertain for which cases spirometric testing is useful. The same is true for the assessment of airway lability by repeated peak flow measurements at home.
We studied a random sample of adults in a wide age range , collecting information on respiratory symptoms, spirometric parameters, and peak flow measurements. The aim of the study was to investigate whether subjects with respiratory symptoms are more likely to have impaired lung function or increased airway lability, and whether this association is stronger in older subjects.
Methods

DATA COLLECTION AND ANALYSES
In the city of Groningen, The Netherlands, an age stratified random sample of 750 men and 750 women aged were invited to participate in a respiratory survey. Data on respiratory symptoms and smoking habits were collected by means of the standardised questionnaire of the ECRHS.8 Symptoms were defined as: (1) wheezing or whistling without having a cold at any time in the last 12 months (wheeze); (2) shortness of breath when walking with other people of their own age on level ground (dyspnoea > grade 3); (3) woken up by an attack of shortness of breath at any time in the last 12 months (nocturnal dyspnoea); (4) cough, usually first thing in the morning, during the day or at night in the winter (cough); (5) phlegm, usually first thing in the morning, during the day or at night in the winter (phlegm); (6) presence of a runny or stuffy nose or itchy watering eyes, cough, wheeze or sneeze, tightness in the chest, or shortness of breath when near animals or trees, grass, flowers or with increased levels of pollen (history of allergy). Subjects who denied having any of these symptoms were considered to be asymptomatic and were further described as the "no symptom" group. The cumulative amount of cigarettes ever smoked was cal-culated and expressed in pack-years ( the number of respiratory symptoms (logistic regressions with adjustment for gender, age, height, pack-years). Odds ratios were considered significant if the 95% confidence interval did not include the value 1. Diurnal variation in PEF of more than 10% was considered to be abnormal. Above this limit diurnal variation in PEF was defined as "high diurnal PEF variation". Between day variation in PEF above 8% (95th percentile) was considered to be abnormal and defined as "high between day PEF variation". Logistic regression was performed to estimate the odds ratios on either of these two forms of high PEF variability depending on the number of respiratory symptoms (with adjustment for gender, age, height, and pack-years).
Distributions of FEVI, PEF or PEF variability were inspected visually by normal probability plots of the standardised residuals of the total population and tested formally by the Kolmogorov-Smirnov test. Parametric tests were used to analyse normal distributions and, for skewed distributions, log transformations were performed to achieve normalisation. Analyses were performed on these log transformed data. Means were transformed back to normal units (geometric means) unless otherwise stated. Differences between means were tested using t tests or analyses of covariance by multiple regression method (ANCOVA). Differences between proportions were tested using x2 tests. All tests were two sided and p values of <0-05 were considered significant. To investigate the association of symptoms with lung function and age, stepwise multiple regression analyses were performed including interaction terms of the separate symptoms with age. All analyses were performed with the SPSS/PC+ V4-0 package. This study was part of the European Community Respiratory Health Survey, a multicentre study on respiratory health.8
Results
Of the 1500 subjects who were invited to participate in the ECRHS, 836 (56%) responded.
Responders were more likely to be older and to have symptoms than non-responders, but these differences were small and not significant. PEF measurements were made in a group randomly chosen from these responders. Of the 579 subjects who were randomly asked to join the current study 573 (99%) agreed to participate. 7 All had performed lung function testing and completed the questionnaire. A completely filled in and readable PEF recording form was received from 520 subjects (90 8%) and their data were analysed. The group who failed to return a properly filled in form (n = 53) did not differ from the analysed group in age and sex distributions, but contained relatively more current smokers and less never smokers (%2 test, p<0-001). As the mean PEF values of the study population on the first day were significantly lower than on the other days, the data from day 1 were excluded from the analyses. After this exclusion, nine subjects had less than the required five days and their data were not analysed. Data of 511 subjects (265 1) , being highest in the "no symptom" group and lowest in those who reported > 3 symptoms (p<0001 adjusted for sex, age, height, and pack-years). Similar significant differences between symptom groups were found for PEF % predicted (fig 2) (p<00001 adjusted for sex, age, height, and pack-years).
There was a positive association between the number of symptoms and the magnitude of the diurnal PEF variation, with the highest mean variation in subjects reporting > 3 symptoms and the lowest mean variation in the "no symptom" group (fig 3) (p<0001 adjusted for sex, age, height, and pack-years). The same positive association was found between the number of reported symptoms and the between day variation in PEF (fig 4) . Table 3 Regression coefficients # (with standard error (SE) and p values) resulting from multiple regression analyses with respiratory symptoms as independent variables and FEV,, PEF, diurnal PEF variation and between day PEF variation respectively, as dependent variables, adjusted for packyears, sex, mean centred age, mean centred height, and other respiratory symptoms Variable FEV, ( (table 3) .
To estimate the odds ratios for "low PEF", "low FEV1'", "high diurnal PEF variation", and "high between day PEF variation" in association with the number of respiratory symptoms logistic regressions were performed (table  4) . Subjects who reported having three or more symptoms had greater odds for low morning PEF (OR=44), low FEV1 (OR=7-6), high diurnal PEF variation (OR=4-4), and high between day PEF variation (OR=6-6) than those with no symptoms (table 4). The odds ratio for low FEV1 was at least four times greater in subjects with any symptom than in those without symptoms.
Age modified the association between nocturnal dyspnoea and between day variation in PEF (J=0-002, p<0005). Older age groups with nocturnal dyspnoea thus had a greater variation in PEF between days than might be expected based on age, height, sex, and packyears. Adjustment for initial PEF did not change this significant interaction. The PEF had a significant negative interaction with the presence of cough and age (13= -1-34, p<0-001). Thus, in older patients cough was associated with lower PEF values than might have been expected on the basis of age, height, sex, and pack-years. This interaction term remained significant after adjustment for initial PEF.
Discussion
These results show that approximately 50% of a random population of adults reported one or more respiratory symptoms. Older people tended to report symptoms more often and the proportion of subjects with two or more symptoms increased with age. On average, subjects with wheeze, dyspnoea > grade 3, and nocturnal dyspnoea had significantly lower levels of FEV, (% predicted). Subjects with nocturnal dyspnoea and cough had significantly lower levels of PEF (% predicted). With increasing numbers of symptoms the mean levels of FEV, and PEF were lower. On average, subjects with two or more symptoms had a seven times greater risk of significant impairment of FEV1 (<70% predicted). Subjects with three or more symptoms had a four times higher risk of a PEF of <70% predicted and a high diurnal PEF variation (>10%) than This study was performed to determine whether the presence of respiratory symptoms was associated with impairment of lung function. The symptoms we asked for were prevalent in this study population. More than any specific symptom, the presence of several symptoms appeared to be strongly associated with significant impairment of lung function. This association did not change when those subjects with doctor diagnosed asthma (n= 39) were excluded.
Significant impairment of lung function was defined as an FEVy of <70% predicted. As the dependency of lung function on age is curvilinear, this may result in an overestimation ofthe proportion ofolder subjects with an FEV1 of <70% predicted. However, we investigated several models in relation to the age variable and found that the linear model fitted the best. For the current population an FEV, of <70% therefore seems to be a legitimate definition of significant impairment of lung function for the whole group.
One cannot be sure ofthe underlying process responsible for the altered relationship between nocturnal dyspnoea and cough, on the one hand, and lung function in the older subjects on the other. It is possible that cardiac disease, which frequently occurs with increasing age, affects this relationship. However, the results did not change when the variable "use of heart medication" was included in the analyses, nor when the subjects who reported the use ofheart medication were excluded from the analyses. This does not permit conclusions, however, as we did not perform clinical diagnostic measurements to quantify cardiac disease when subjects reported use of heart medication. Further studies on the effects of comorbidity on lung function with increasing age are required.
Because the current analyses were performed on data collected in a cross-sectional study, no conclusions can be drawn on whether respiratory symptoms preceded or were a result of lower FEV, or PEF or increased airway lability.
This study shows than an increasing number of symptoms occur with increasing age. A higher risk of significant impairment of FEV, is present for subjects with two symptoms or more. General practitioners should therefore ask subjects about symptoms such as nocturnal dyspnoea and cough when any respiratory symptom is mentioned, especially if subjects are elderly. As adaptation to respiratory symptoms in elderly subjects appears to be common,24 general practitioners should be particularly alert to every patient who reports such symptoms when attending his or her practice. The presence of more than one respiratory symptom in elderly patients should alert the practitioner to the possibility of chronic impairment of lung function.
